P

Pfizer

Makes cancer drugs, vaccines and other medicines

Enrollment – Focused Clinical Study Team Lead

Part-TimeUpdated on 10/20/2026Deadline 10/27/26
No salary listed
Senior
Bachelor's, Master's, PhD, MD
Groton, CT, USA+1 moreMore locations: United States
HybridAbout 2.5 days per week in the office at the current work location.
Biology & BiotechClinical Research Operations
No H1B Sponsorship

About the job

Requirements
  • A bachelor's degree and at least 8 years of experience are required.
  • Develop and maintain an integrated U.S. enrollment strategy, aligned baseline activation and recruitment plans, and a stakeholder map.
  • Maintain a prioritized U.S. site view that includes activation status, targeted representation, site-level actions, outreach history, and study-specific feedback.
  • Maintain a shared U.S. enrollment view connecting activation, recruitment, targeted representation, site risks, mitigations, and global plan impact.
  • Maintain an action and decision log with accountable owners, due dates, and effectiveness checks.
  • Prepare executive-ready materials and coordinated responses for ERMF, OSGT, R&D LT, MCI, and other leadership requests.
  • Document lessons learned and a handoff plan at the conclusion of the assignment.
  • Candidates must be authorized to work in the United States by any employer and have permanent work authorization in the United States.
Responsibilities
  • Partner with the study team to advance U.S. enrollment performance and maintain an integrated U.S. enrollment strategy and action plan aligned with the global study strategy and required U.S. enrollment contribution.
  • Contribute to country and site feasibility questionnaire development and site selection decisions; pressure-test DVSO scenarios.
  • Facilitate alignment across the core and extended study team on baseline plans for U.S. site activation and recruitment, including shared assumptions, milestones, dependencies, and accountabilities.
  • Work with colleagues aligned to deliver U.S. enrollment to test the U.S. site activation baseline plan, build visibility into progress, and agree on early mitigations when milestones are at risk.
  • Maintain a prioritized view of U.S. sites based on activation status, readiness, projected contribution, targeted representation, recruitment barriers, and actual performance.
  • Bring Clinical, Site Care Partner, and FMD colleagues together to align site outreach, share insights and commitments, and ensure study-specific feedback informs coordinated next steps.
  • Ensure priority sites have practical action plans addressing patient identification, referral pathways, pre-screening, local barriers, and appropriate use of available recruitment tactics.
  • Partner with the Recruitment Strategist to prioritize contracting and increase appropriate use of available recruitment tactics, patient-matching capabilities, site support resources, and approved participant-facing materials in accordance with CMCD requirements; pilot novel strategies and tactics as appropriate.
  • Facilitate regular enrollment reviews that provide a shared view of progress, risks, decisions, owners, due dates, and effectiveness checks across core, extended, governance, and site-facing colleagues.
  • Monitor site activation, screening, screen failure, randomization, site productivity, targeted representation, and forecast-versus-actual performance; connect U.S. delivery to global recruitment plans and recommend corrective actions.
  • Use the Enrollment Risk Management Framework to create a forum for surfacing site and study risks early, jointly developing mitigations, and seeking timely support through agreed escalation pathways when barriers extend beyond the team's control.
  • Serve as a collaborative connection point for leadership and governance engagement, including ERMF, OSGT, R&D LT, and MCI; partner with the study team to prepare concise materials, align messages, clarify decisions needed, and recommend practical actions.
  • Build two-way feedback loops among governance partners, the study team, and site-facing colleagues; translate feedback into jointly owned actions and share reusable lessons across U.S. oncology enrollment efforts.
Desired Qualifications
  • A master's degree and at least 7 years of experience, or a PhD and at least 5 years of experience, or an MD and at least 4 years of experience.

About the company

Pfizer discovers, makes, and sells prescription medicines and vaccines for patients, doctors, and governments worldwide, with large businesses in vaccines, cancer, heart disease, and rare diseases. In 2020, its COVID-19 shot, developed with German partner BioNTech, became the first COVID-19 vaccine authorized in the United States. Its scientists find drug candidates and run clinical trials to prove they are safe and effective, and Pfizer then manufactures approved products in its own plants, earning most of its money from patented drugs before cheaper generic copies arrive. Pfizer was founded in 1849 as a chemicals business in Brooklyn and is based in New York City.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Newer drugs carry the business: launched and acquired products grew 18% operationally in Pfizer's August 2026 quarterly report.
  • The outlook improved: in August 2026, Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion.
  • Vaccine scientists get room to grow: Pfizer's $470 million Pearl River, New York research expansion is designed for 370 workers.

What critics are saying

  • Expect more site cuts: in November 2025, Pfizer moved to shrink Swiss staff from about 300 to roughly 70.
  • Generics will erase sales: Pfizer expects patent losses to cut $17 billion to $18 billion of yearly revenue through 2028.
  • Pfizer is chasing obesity leaders: Metsera's monthly shot showed 12.3% weight loss at 28 weeks in February 2026 data.

What makes Pfizer unique

  • Pfizer bought its way into cancer: its Seagen buyout added antibody-drug conjugates, which carry chemotherapy straight to tumors.
  • Pfizer is betting on monthly obesity shots: Metsera's berobenatide is dosed once a month, unlike weekly Wegovy and Zepbound.
  • Pfizer leans on one partnered heart drug: blood thinner Eliquis, sold with Bristol Myers Squibb, brings about 14% of revenue.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Hybrid Work Options
  • Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-3%

2 year growth

-3%
Yahoo Finance
Oct 19th, 2026
Five low-beta dividend stocks: Pfizer yields 5.83%, Coca-Cola raises payout since 1999

Five defensive dividend stocks offer income with less volatility than the broader market, according to a 24/7 Wall St. analysis. All five have a beta well below 1, meaning they have historically moved less than the market. Pfizer leads with a forward yield of 5.83% at $29.49 a share. AT&T yields 4.77% at $23.27, and its $1.11 dividend uses about 42% of 2026 free cash flow guidance of $18B+. Debt of $144B is its main risk. Dominion Energy yields 4.24%, while Coca-Cola and Colgate-Palmolive each yield 2.27%. Coca-Cola has raised its dividend every year since 1999, and Colgate's next ex-dividend date is October 20, 2026.

Yahoo Finance
Oct 15th, 2026
GSK beats Pfizer as dividend stock: 39% payout vs 89% of free cash flow

GSK looks the better dividend stock than Pfizer, according to a comparison of the two drugmakers, which both face major patent losses before 2030. Pfizer yields 6.3% and GSK 4.1%. Over the twelve months to June 2026, Pfizer paid out 89% of its free cash flow in dividends ($9.79 billion of $10.98 billion), against 39% at GSK (£2.67 billion of £6.90 billion). Pfizer's chief executive officer, Albert Bourla, said the dividend will be maintained even in "the most stretched scenarios." Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion. GSK raised its dividend 17.6% in fiscal 2025 after an earlier cut, and Q2 2026 sales rose 5%. Its main risk is debt: net debt rose to £22 billion after the Nuvalent acquisition.

Yahoo Finance
Oct 14th, 2026
Pfizer's 6% dividend pays investors to wait as oncology pipeline drives growth beyond COVID-19

Pfizer offers a dividend yield of just over 6% while it builds growth beyond its COVID-19 products. The drugmaker declared a quarterly dividend of $0.43 in June 2026, its 351st consecutive quarterly payment. In the second quarter, revenue from launched and acquired products rose 18% year over year. Pfizer raised the midpoint of its full-year guidance, helped by stronger non-COVID sales from drugs such as Eliquis, Padcev, and Vyndaqel. Oncology is the next focus. Pfizer is investing in antibody-drug conjugates and bispecific antibodies, and it entered a global collaboration with Innovent Biologics covering 12 early-stage cancer programs. Not every experimental drug will succeed, but a broader pipeline improves the odds. If new medicines work, the share price could rise on top of the dividend income.

Yahoo Finance
Oct 13th, 2026
Six high-yield dividend stocks fail the payout test, from Ford to Whirlpool's 9.37% mirage

High dividend yields can hide weak payouts, and a four-step test helps separate real income from traps. It checks earnings with one-offs stripped out, full-year free cash flow against dividends, management's explanation, and whether debt funds the gap. Ford yields 4.99% and shows a trailing EPS of -$1.88, caused by $4.2B in one-time charges. Its debt-to-equity of 4.66 leaves the $0.60 dividend exposed to a downturn. Pfizer yields 6.03%, but its free cash flow yield is 5.60%. Clorox's roughly $405M of free cash flow fell short of about $601M in dividends. Whirlpool fails every step. It cut its quarterly dividend from $1.75 to $0.90 in 2025, paid no common dividend in the second quarter of 2026, and its shares are down 59.48% since the end of 2025. 3M and Dow pass, with payouts now covered by cash.

Yahoo Finance
Oct 12th, 2026
UPS, Pfizer, Kraft Heinz and Ford dividends at risk as payouts outstrip earnings

Four blue chip companies, UPS, Pfizer, Kraft Heinz, and Ford, may struggle to sustain their dividends, according to an analysis of their earnings, cash flow, and debt. UPS yields 7.02% and pays out about 121% of its GAAP earnings. Pfizer yields 6.10%, with a GAAP payout ratio of about 226%; its 2025 free cash flow of $9.076 billion fell short of $9.771 billion in dividends. Kraft Heinz yields 6.82%, but its trailing GAAP earnings per share are −$2.88 after $7.4 billion in impairments. Ford yields 4.98% after an $8.162 billion loss in 2025, and its debt-to-equity ratio is 4.66. All four companies say their payouts are safe, and each points to adjusted earnings guidance that covers the dividend.